Weitere Verbundprojekte

Landes-Offensive zur Entwicklung Wissenschaftlich-ökonomischer Exzellenz – kurz: LOEWE – ist der Titel des Forschungsförderungsprogramms, mit dem das Land Hessen seit 2008 wissenschaftspolitische Impulse setzen und damit die hessische Forschungslandschaft nachhaltig stärken will.

Anwendungsorientierte Arzneimittelforschung
(seit 2012)
NNCS − Non-neuronale cholinerge Systeme (seit 2012) SynChemBio - Innovative Synthesechemie für die selektive Modulation biologischer Prozesse (ab 2014)
     
 
Ub-Net - Der geheime Code des kleinen Proteins Uniquitin CGT − Zentrum für Zell- und Gentherapie Frankfurt

 DynaMem - Dynamik von Membranen

     

LOEWE Zentrum: Translationale Medizin & Pharmakologie

150x100 loewe tmp

Das LOEWE-Zentrum für Translationale Medizin und Pharmakologie TMP verfolgt eine anwendungsbezogene biomedizinische Forschung zum Nutzen der Gesellschaft und der Wirtschaft. Die Forschungsgebiete des Zentrums orientieren sich somit an dem aktuellen medizinischen Bedarf in der Arzneimittelforschung und -entwicklung.

Beteiligt sind alle Institute mder Pharmazie

Weitere Verbundprojekte:

150x100 bmbf

KMU-innovativ-14: Oliven gegen das Vergessen

NeurOliv: "Erstmalige biotechnologische Herstellung und Reindarstellung von Oliven-Polyphenolen und untersuchung zur nutritiven Prävention neurodegeneariver Erkrankungen." (Seit 2015)

Apl. Dr. Günter Eckert, TU Darmstadt, N-Zyme Biotec GmbH


Orbito logo

ORBITO - Oral biopharmaceutics tools

Most drugs are taken orally, as tablets or capsules for example. However, designing these pharmaceutical products in such a way that the active ingredient is absorbed at an appropriate rate and extent by the gut is far from easy. The ORBITO project aims to enhance our understanding of how orally-administered drugs are taken up from the gastrointestinal tract into the body, and apply this knowledge to create new laboratory tests and computer models that will better predict the performance of these drugs in patients.


Translocation png

As part of the IMI antimicrobial resistance (AMR) programme New Drugs for Bad Bugs, TRANSLOCATION aims to increase the overall understanding of how to get antibiotics into multi-resistant Gram-negative bacteria such as Escherichia coli and Klebsiella pneumoniae and how to stop the bacteria from ejecting the drug. In sharing the knowledge and data discovered, TRANSLOCATION will develop guidelines for designing and developing new drugs to tackle antibiotic resistance and create an information centre for pre-existing and on-going antibacterial research data which will be used to establish best practices for future antibacterial drug discovery efforts.


iNEXT: Infrastructure for NMR, EM and X-ray crystallography for translational research

iNEXT (infrastructure for NMR, EM and X-rays for Translational research) will provide high-end structural biology instrumentation and expertise, facilitating expert and non-expert European users to translate their fundamental research into biomedical and biotechnological applications. iNEXT brings together leading European structural biology facilities under one interdisciplinary organizational umbrella and includes synchrotron sites for X-rays, NMR centers with ultra-high field instruments, and, for the first time, advanced electron microscopy and light imaging facilities (23 partners). Together with key partners in biological and biomedical institutions, partners focusing on training and dissemination activities, and ESFRI projects (Instruct, Euro-BioImaging, EU-OPENSCREEN and future neutron-provider ESS), iNEXT forms an inclusive European network of world class.


EUROPOL

NMR and MRI play unique roles in contemporary Science, from Physics, Chemistry and Biology, to clinical research and diagnosis. Despite its irreplaceable role, further progress in NMR and MRI is hampered by sensitivities that are much lower than those of alternatives such as mass-spec, or PET. The prospects of solving this problem by “bigger machines” are uncertain and of poor return, given the high maturity already achieved by NMR/MRI.


HaemMetabolome - Deciphering the Metabolism of Haematological Cancers

It has long been realised that metabolism is central to cellular development, proliferation and homeostasis. Collectively, aberrations in metabolism are now recognised as a major hallmark of cancer, opening new avenues for personalised medicine. As haematological malignancies are multi-factorial diseases, our main emphasis will be on the integration of biomedical multi-omics data and computational systems modelling with the ultimate aim to understand metabolic regulation in haematological cancers. HaemMetabolism is design to unravel the regulatory mechanisms that link cell cycle control and metabolism.


Ausgelaufene Projekte

 
AmbiProbe − Massenspektro-metrische in-situ-Analyse für Gesundheit, Umwelt, Klima
und Sicherheit
(2010-2013)

LiFF - Lipid Signaling Forschungszentrum Frankfurt (2008-2011) NeFF − Neuronale Koordination Forschungsschwerpunkt Frankfurt (2011-2014)
     
   
Onkogene Signaltransduktion Frankfurt (2010-2013)

   
     
   
NanoBiC: Research collaboration funded by the Beilstein-Institute